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Abstract 
The cytomegalovirus (CMV) immediate early promoter has been extensively developed and 
exploited for transgene expression in vitro and in vivo, including human clinical trials. The 
CMV promoter has long been considered a stable, constitutive and ubiquitous promoter for 
transgene expression. Using two different CMV-based promoters, we found an increase in 
CMV-driven transgene expression in the rodent brain and in primary neuronal cultures in 
response to methamphetamine, glutamate, kainic acid, and activation of G-protein coupled 
receptor signaling using designer receptors exclusively activated by designer drugs 
(DREADDs). In contrast, promoters derived from human synapsin 1 (hSyn1) gene or 
elongation factor 1a (EF1a) did not exhibit altered transgene expression in response to the 
same neuronal stimulation. Overall, our results suggest that the long standing assertion that 
the CMV promoter confers constitutive expression in neurons should be reevaluated and 
future studies should evaluate the activity of the CMV promoter in a given application. 
 
Introduction 
Due to strong expression and compatibility with numerous cell types, promoters derived from 
the enhancer region of the cytomegalovirus (CMV) immediate early (IE) promoter are among 
the most common for general expression vectors.1,2 Its reputation as a source of stable, long-
term expression has even allowed the CMV promoter to be used in clinical trials for gene 
therapy in the central nervous system.3,4 The CMV promoter/enhancer contains an array of 
regulatory elements including multiple binding sites for cellular transcription factors, such as 
ATF/CREB (activating transcription factor/cAMP response element binding protein), NF-
κB/Rel, (nuclear factor κB/Rel), SP-1 (specificity protein 1), ELK-1 (ETS transcription 
factor), RAR-RXR (retinoic acid receptor family), and AP-1 (activator protein 1).5 The 
activation of these transcription factors is known to be rapid and affected by a wide range of 
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acute stimuli, including neuronal transmission, growth factors, cell stress and inflammation. 
Indeed, CMV reactivation as a consequence of wild-type CMV-IE promoter activation has 
been suggested in response to increased cAMP levels, activation of protein kinase C, 
proinflammatory cytokines or lipopolysaccharide, and heat shock.6-10 
 
Despite the above-mentioned possible confounding effects of transcription factor activity 
regulating CMV-driven transgene expression, the CMV promoter continues to be widely used 
to drive transient or long-term expression of transgenes in vitro and in vivo without 
addressing potential effects of experimental treatments on transgene expression. During our 
studies on neurotoxic effects of the widely abused stimulant methamphetamine (Meth), we 
found indications of a treatment-induced upregulation of CMV-driven transgene expression, 
leading to strong false-positive results in our model system. Using different in vivo and in 
vitro models for neuronal activation, we observed a strong interaction between neuronal 
activation and CMV promoter-controlled transgene expression, creating a bias that may 
influence fundamental pre-clinical, as well as clinical, research findings. 
 
Results 
Subcutaneous methamphetamine affects CMV promoter activity in the rat striatum 
To study changes in brain-derived transgene expression, we set up a method for detection of a 
secreted, luminescent reporter protein in the rat brain by repeated cerebral spinal fluid (CSF) 
sampling from rat cisterna magna (Figure S1A). Intrastriatal injections of increasing titers of 
an adeno-associated virus serotype 1 (AAV1) vector encoding the constitutively secreted 
Gaussia Luciferase (GLuc) led to corresponding increases in rat CSF GLuc activity, thereby 
establishing a method to longitudinally monitor transgene expression in the brain (Figure 
S1B). 
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A group of rats received bilateral injections of the AAV1-CMV-GLuc vector and, following 
collection of three baseline CSF samples, rats were injected with four subcutaneous (s.c.) 
injections of saline or Meth 2.5 mg/kg given with 2-h intervals (Figure 1A) following a 
neurotoxic model of Meth exposure.11. Meth-injected rats had a robust 5.4-fold increase in 
GLuc activity in their CSF at 8 h after the first Meth injection (Figure 1B). A subset of rats 
were sampled 16 h and 40 h later, indicating that the levels of GLuc protein had returned to 
baseline levels within the first two days after the Meth challenge (Figure 1B). Using qPCR, 
we detected significantly higher levels of GLuc mRNA in the striatum of Meth-treated rats at 
8 h after the first Meth injection compared to vehicle control group (Figure 1C). The observed 
increase in mRNA significantly correlated to the increase in CSF GLuc activity (Figure S1C), 
indicating that Meth altered expression of the transgene. Meth and saline groups had similar 
levels of transgene DNA in their striatum at the end of the study (Figure S1D) and similar 
CSF GLuc activity at baseline (Figure S1E), excluding basal inter-group variations as possible 
explanation for the observed differences in GLuc protein and mRNA from Meth and saline 
groups. 
 
The observed effect of Meth on transgene expression could be due to inherent characteristics 
of a Meth-induced stimulatory effect on overall transcriptional activity. Therefore, we 
constructed AAV1 vectors with GLuc expression under the control of the human eukaryotic 
translation elongation factor 1α (EF1α) or synapsin 1 (Syn1) promoter and injected them 
bilaterally into the rat striatum. After verification of similar baseline GLuc CSF levels 
between treatment groups (Figure S1F-G), rats were injected with saline or Meth. In contrast 
to the AAV1-CMV-GLuc vector, Meth did not affect the GLuc protein levels in CSF nor 
GLuc mRNA levels in the striatum for vectors with the Syn1 (Figure 1D-E) or EF1α promoter 
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(Figure 1F-G), indicating that the Meth effect on the AAV1-CMV-GLuc vector is specific to 
the vector promoter. A lack of Meth-induced increase in GLuc activity in the CSF of rats 
injected with AAV1-Syn1-GLuc or AAV1-EF1α-GLuc also excluded a drug-related increase 
in secretion as the cause of increased extracellular GLuc activity in the AAV1-CMV-GLuc-
injected rats. 
 
In addition to the CMV-IE promoter, the promoter/enhancer region in our AAV1-CMV-GLuc 
vector contains a chimeric intron with sequences from the first intron of the human β-globin 
gene and the intron of an immunoglobulin gene heavy chain variable region (see Table S1 for 
promoter sequence). We will hereby refer to this promoter as CMV’, and the vector as AAV1-
CMV’-GLuc. To test if the intron proportion of the CMV’ promoter contributed to the Meth-
induced increase in transgene expression, rats were intrastriatally injected with AAV1 vectors 
carrying the GFP transgene under the control of the CMV’ promoter or the CMV-IE promoter 
(CMV). Four s.c. injections of 2.5 mg/kg Meth (two hours apart) resulted in similar 
approximately 5- to 7-fold increases in striatal levels of GFP mRNA at four weeks post-
transduction (Figure 2A), supporting that the CMV-IE portion of the promoter/enhancer is 
responsible for the Meth-induced upregulation of transgene expression. 
 
Amphetamines have long been used in pre-clinical Parkinson’s disease research to evaluate 
the function of the nigrostriatal dopaminergic pathway and the therapeutic potential of 
experimental treatments, including overexpression of therapeutic proteins.12,13 To test if a 
protocol widely used to detect amphetamine-induced asymmetric behavior in rodent models 
of Parkinson’s disease will alter transgene expression, we injected unilaterally 6-
hydroxydopamine-lesioned rats overexpressing GFP under the CMV’ promoter in the 
striatum14 with a single s.c. dose of Meth (2.5 mg/kg). Even after a single Meth injection 34 
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weeks after striatal transduction with AAV-CMV’-GFP, we detected a significant effect of 
Meth on GFP mRNA levels in the lesioned tissue (two-way ANOVA, Meth versus no Meth 
(0 h time point in Figure 2B) between effect, F3,16 = 14.8, p < 0.001). In addition, we detected 
a time-dependent increase in GFP mRNA levels in the striatum, with an approximate 
maximum 5.6-fold increase four hours post-injection that returned to baseline levels within 
eight hours (Figure 2B). 
 
Activation of excitatory pathways induces CMV-dependent transgene expression in 
primary cortical neurons 
Meth has been reported to alter the activation and binding of several transcription factors, 
including AP-1,15,16 CREB,16,17 and NF-κB.18 These transcription factors are also important in 
the activation of CMV-driven expression,5 and an increase in their activity could be driving 
the observed Meth-induced increase in transgene expression. Thus, we hypothesized that 
other substances known to indirectly or directly modify the activity of these transcription 
factors could also alter transgene expression under the control of the CMV promoter. Indeed, 
a 24-h treatment with 100 µM kainic acid or glutamate19,20 increased both secreted (Figure 
3A) and intracellular (Figure 3D) GLuc activity in rat primary cortical neurons transduced 
with AAV1-CMV’-GLuc. On the contrary, application of excitatory amino acids to cells 
transduced with AAV1-Syn1-GLuc or AAV1- EF1α-GLuc caused a significant decrease in 
extracellular (Figure 3B, C) and intracellular (Figure 3E, F) GLuc levels, likely due to 
treatment-induced cell toxicity (Figure 3G). 
 
Stimulation of neuronal activity by the introduction of designer receptors or channels that can 
be activated chemically or optically has been extensively exploited over the past few years to 
dissect neuronal pathways in mammals. Considering the effects of excitatory amino acids on 
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CMV-driven transcription, we introduced Cre-dependent expression of the DREADDs 
(designer receptors exclusively activated by designer drugs) hM3D (Gq) or hM4D (Gi)21 into 
rat primary cortical neurons together with our CMV’-GLuc reporter. A 24-h incubation in the 
DREADD ligand, clozapine N-oxide (CNO; 0.03-3 µM), resulted in a significant dose-
dependent increase in both secreted GLuc protein (Figure 4A, left side) and GLuc mRNA 
(Figure 4B, left side) in cells transduced with hM3D, indicating that Gq-activating signaling 
pathways or compounds can affect CMV-driven transgene expression. In cells overexpressing 
hM4D, the transgene expression was unchanged following exposure to CNO (Figure 4A-B, 
right sides). The overall expression of hM3D (Figure S2A) and hM4D (Figure S2B) was 
comparable in the different treatment groups. Again, expression of GLuc under the control of 
the Syn1 (Figure S2C-D) or EF1α promoter (Figure S2E-F) did not change in response to 
CNO treatment in cells overexpressing hM3D or hM4D, although we did detect a small, but 
significant, increase in Syn1-GLuc mRNA levels following activation of hM3D receptors 
with 3 µM CNO (Figure S2D), indicating that an activation of Gq-dependent pathways may 
also have an effect on Syn1 promoter activity. However, this small increase was not reflected 
at the protein level (Figure S2C). 
 
The observations that the CMV promoter can be induced by a variety of neuronal stimulants 
creates a new caveat when selecting promoters for neuroscience applications. This knowledge 
also provides opportunity to exploit this property to provide transgene expression in response 
to neuronal stimulation. Previous work has shown that expression of an anti-Meth antibody 
can reduce Meth exposure in the brain and serum.22 Based on our observations that Meth 
induced CMV promoter, we tested whether Meth could induce expression of MethAb when 
put under control of the CMV promoter. HEK293 cells were transfected with pAAV-MethAb, 
in which the MethAb gene was expressed by the CMV promoter. At two hours post-
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transfection, cells were treated with Meth (100 µM) for 20 hours, and, after that, the MethAb 
mRNA levels in the cell lysates were examined by qRT-PCR analysis (Figure 5). A 
significant difference in MethAb mRNA production was found after Meth treatment (ß-actin 
as the reference gene: F2,15 = 71.65, p < 0.0001, one-way ANOVA; GAPDH as the reference 
gene: F2,15 = 78.89, p < 0.0001, one-way ANOVA). Post hoc Dunnett’s comparison test 
indicated that treatment with 100 µM Meth significantly enhanced MethAb mRNA 
production (ß-actin as the reference gene: 2.59 ± 0.217 vs 1 ± 0.16, p < 0.0001; GAPDH as 
the reference gene: 2.35 ± 0.18 vs 1 ± 0.15, p < 0.0001), as compared to the control group 
(pAAVMeth + 0 µM Meth). These data show that Meth induced expression of the MethAb 
transgene driven by the CMV promoter. 
 
Discussion 
Our results suggest that a general increase in neuronal activity, whether through excess of 
excitatory amino acids, activation of G protein-coupled signaling, or pharmacological 
stimulation of dopaminergic signaling, can have a strong activating effect on the CMV 
promoter. Although we cannot exclude that some of the observed activation of the CMV 
promoter may be a secondary outcome of neuronal activation with downstream neurotoxic 
pathways serving as the primary activator of transcription, we do show that CMV activation 
does not generalize to other commonly used transgene promoters. Given these findings, 
caution should be applied when using the CMV promoter to drive expression of effectors of 
neuronal activation. Our results identify a new caveat for designing transgenic studies and 
suggest a need to re-evaluate results generated in studies with concomitant use of CMV-
driven transgene expression and stimulatory treatments. These studies range from research on 
addiction and effects of stimulatory substances on neurotransmission and neurotoxicity, to 
studies involving, e.g., kainic acid-induced seizures or using Meth as a tool to manipulate 
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dopaminergic signaling in animal models. Our observation that a single dose of Meth can 
induce a transient increase in transgene expression in the rat brain when administered eight 
months after transduction suggests a potential confounding effect on treatment outcome and 
emphasizes the need for evaluating transgene expression levels proximal to manipulations 
done months after transgene delivery. Although the effect on transcription was transient, the 
resulting change in transgene-mediated protein expression will depend on the magnitude of 
gene expression induction as well as the half-life and biology of the protein (e.g. neurotrophic 
factors, such as glial cell line-derived neurotrophic factor, GDNF, have long-lasting effects 
following a single intracranial bolus injection23). Most notably, several clinical trials for 
human gene therapy of CNS disease have used AAV vectors with CMV promoters,3,4 the use 
of which may have altered the expected outcomes based on the preclinical model data where 
amphetamines are often used to probe behavioral phenotypes at various times following gene 
delivery. 
 
Conversely, our findings could also be exploited for experimental or therapeutic purposes. For 
example, amphetamine-derivatives approved for clinical use could be used to increase the 
expression of transgenes in the brain, thereby decreasing the virus titers needed for efficient 
transgene expression. Our results suggest that the activation of transgene expression is 
transient and a cessation of drug delivery would quickly bring down the levels of exogenous 
protein production. We previously demonstrated that systematic administration of virus AAV-
MethAb induced persistent MethAb expression in the periphery, lowered the plasma Meth 
level, and attenuated Meth-induced hyperactivity and stereotyped behavior in adult mice.22 In 
the current study, we found that Meth could stimulate the production of MethAb mRNA 
through a CMV promoter, which was likely contributing to our positive findings in our 
previously published work. Here, we used non-dopaminergic cells, HEK293 cells to show 
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altered CMV transcription by Meth. Non-dopaminergic response of Meth has been previously 
reported in HEK293 cells. Meth alters Ca2+-activated potassium channels (KCa1.1, BK) in 
HEK293 cells expressing GFP-α subunits of the BK channel; this effect was blocked by 
protein kinase C inhibitor BIM-I.24 The new data presented herein further support the use of 
CMV promoter-driven MethAb expression as a therapeutic intervention for the treatment of 
Meth dependence and intoxication. 
 
In addition to the implications of our findings for CMV-mediated transgene expression, our 
data provide additional context for studies of the human CMV. For example, CMV shedding 
in HIV-infected Meth users on antiretroviral therapy suggest Meth induces reactivation of 
latent CMV infection.25 Although this could be an indirect result of Meth’s effects on the 
immune system with loss of control of the latent virus,25 based on our results it is reasonable 
to hypothesize that Meth impacts the transcription of CMV-IE genes. Importantly, increased 
shedding of CMV in HIV-patients has been linked to an increase in T cell activation and 
proliferation, as well as higher levels of HIV DNA in blood cells,26 possibly affecting HIV 
outcome and morbidity. 
 
Lastly, in addition to the models used in the current study, our results suggest that other 
stimulatory manipulations may act on the CMV promoter. We therefore strongly recommend 
researchers working with CMV-related promoters to assess the transgene expression in their 
model systems. Although we focused solely on the effects in central nervous system, we also 
predict CMV-driven transgene expression will have activating effects in peripheral tissue in 
response to events previously reported to increase the expression of CMV-IE genes, such as 
inflammation and treatments affecting intracellular signaling pathways involved in 
transcription factor activation.6-9 
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Material and methods 
Viral vectors 
The AAV vectors were produced using serotype 1 capsid proteins as previously described27 
and titered by droplet digital PCR. The following plasmids were used for AAV vector 
production (promoter sequences described in Table S1; plasmids available upon request from 
corresponding authors): 
 
pAAV CMV’ GLuc: The vector has been previously described.28 The promoter region is 
similar to what is used in the pCI-Neo mammalian expression vector (# E1841 Promega, 
Madison, WI). 
 
pAAV CMV’ GFP and pAAV CMV GFP: The pAAV EF1a DIO iRFP (Addgene #47626) 
was edited to replace the region beginning at the trs element in the left ITR and ending with 
the human growth hormone polyadenylation element with a GFP expression cassette driven 
by the CMV’ promoter/enhancer (from AAV CMV’ GLuc) to create pscAAV CMV’ eGFP 
bGHpA (pOTTC552). The CMV’ promoter was then replaced with the CMV promoter 
amplified from pEGFP-C1 (Clontech) to produce pscAAV CMV eGFP (pOTTC730). 
 
pAAV EF1α GLuc and pAAV Syn1 GLuc: The GLuc coding region was amplified from 
pLenti6.3 CMV Manf-sigpep-GLuc-MCS (pOTTC7001) and used to replace the fluorescent 
protein coding region in pAAV EF1α iRFP-FLAG (pOTTC1464) and pAAV SYN1 Nuc-
EGFP-Myc (pOTTC1532) to produce pAAV EF1α GLuc (pOTTC1544) and pAAV Syn1 
GLuc (pOTTC1547), respectively. 
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pAAV hSyn DIO hM3D(Gq)-mCherry (Addgene #44361) and pAAV hSyn DIO hM4D(Gi)-
mCherry (Addgene #44362) were a gift from Bryan Roth (UNC School of Medicine, Chapel 
Hill, NC). 
 
pAAV1 EF1a iCre: The improved Cre coding region29 was amplified from pFos iCre 
(pOTTC161) and used to replace the lox sites and fluorescent protein coding region in pAAV 
EF1a DIO iRFP (Addgene #60057) to produce pAAV1 EF1a iCre (Addgene #89760). 
 
Animals and animal procedures 
All animal protocols were reviewed and approved by the Animal Care and Use Committee 
(ACUC) at the NIDA IRP using the National Institutes of Health guidelines, or by the 
national Animal Experiment Board of Finland. The animals were group-housed in a 12-h 
light/dark cycle, with ad lib excess to rodent chow and water. 
 
Adult male Long-Evans rats (250-290 g, Charles River Laboratories, Wilmington, MA) 
received intracranial AAV1 injections into the striatum in a stereotaxic surgery under 
isoflurane anesthesia. Using a 10-µl Nanofil syringe with a 33-gauge needle coupled to a 
UMP4 microinjector pump (World Precision Instruments, Sarasota, FL), 2 µl of 0.5x1012 
vg/ml were injected 0.0 mm anterior, 3.0 mm lateral, and 5.0 mm ventral from bregma with 
the injection speed 0.5 µl/min, leaving the needle in place 2 min before retraction. Four weeks 
after the intracranial AAV injections, rats received four subcutaneous injections of Meth 2.5 
mg/kg ((+)-Methamphetamine hydrochloride, Sigma-Aldrich, St Louis, MO) or saline given 
with 2-h intervals, adding to a total Meth dose of 10 mg/kg. 
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For the initial virus titer study, ten rats were injected bilaterally with 2 µl AAV1-CMV’-GLuc 
0.5x1010, 0.5x1011, or 0.5x1012 vg/ml. 
 
Wistar rats (Harlan/Envigo, Horst, The Netherlands) injected intrastriatally with 6-
hydroxydopamine and AAV1-CMV’-GFP have been previously described.14 Briefly, three 
weeks following intrastriatal delivery of AAV1-CMV’-GFP, the nigrostriatal pathway was 
partially lesioned with 3 x 2 µg 6-hydroxydopamine.14 To study whether the effect of CMV 
induction can still be seen after long-term transduction, we let the expression continue for 
several months. A single s.c. injection of Meth 2.5 mg/kg was administered to 10.5-months 
old rats, i.e. 31 weeks post-lesion and 34 weeks post-AAV. 
 
Repeated collection of CSF was done from rat cisterna magna under isoflurane anesthesia 
(method adapted from30). The rat head was fixed in a stereotaxic apparatus, with the head bent 
down in an approximately 45-degree angle (Figure S1A). Using a 23-gauge needle attached to 
a 1-ml syringe with PE-50 tubing (Scientific Commodities Inc., Lake Havasu City, AZ), 50 µl 
CSF was withdrawn and stored in -80°C until analysis. 
 
Cell culture 
Rat primary cortical neurons were prepared from Sprague-Dawley embryos as previously 
described31 and in accordance with approved procedures by the National Institutes of Health 
Animal Care and Use Committee. Isolated cells were plated at 6x104 cells/well in 96-well 
polyethyleneimine-coated plates. Fifty percent media exchanges were performed on day in 
vitro (DIV) 4, 6, 8, 11, and 13. On DIV6 transductions were performed with the following 
viruses: AAV1-CMV’-GLuc (5.8x109 vg/ml), AAV1-Syn1-GLuc (5.8x109 vg/ml), AAV1-
EF1α-GLuc (5.8x109 vg/ml), AAV1-EF1α-iCre (1.0x1011 vg/ml), AAV1-Syn1-Dio-
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hM3D(Gq)-mCherry (1.0x1011 vg/ml), AAV1-Syn1-DIO-hM4D(Gi)-mCherry (1.0x1011 
vg/ml). On DIV13, cells were treated with kainic acid (100 µM, Cayman Chemical Company, 
Ann Arbor, MI), glutamate (100 µM, Sigma Aldrich), or clozapine N-oxide (CNO, 0.03, 0.3, 
3 µM, Enzo Life Sciences, Farmingdale, NY) via 50% media exchange. Extracellular media 
samples were collected 24 h post-treatment. Subsequently, a subset of cells were rinsed twice 
with phosphate buffered saline and incubated with lysis buffer (50 mM Tris HCl pH 7.5, 150 
mM NaCl, 1% NP-40, and protease inhibitors (Sigma Aldrich)) for 20 minutes at 4°C. Cell 
viability was assessed 24 h post-treatment via CellTiter96 AQueous One Solution Cell 
Proliferation Assay (MTS assay, Promega). 
 
Detection of Gaussia Luciferase 
For in vivo studies, CSF (5 µl) was transferred to white 96-well plates (Corning, Corning, 
NY) as technical triplicates. Using Biotek Synergy II plate reader (Winooski, VT), the 
luminescence was detected following injection of 100 µl of 100 µM coelenterazine (Regis 
Technologies, Morton Grove, IL). The plate reader parameters were set to an integration time 
of 5 s and a sensitivity of 100. For determination of GLuc activity in vitro, luminescence was 
detected in 5 µl extracellular media or cell lysate following injection of 8 µM coelenterazine. 
 
Real-time quantitative reverse transcription PCR and droplet-digital PCR 
For quantitative PCR, anesthetized rats were decapitated eight hours after the first Meth 
injection and their brains snap-frozen in isopentane. The rat striata were dissected in a 
freezing microtome and processed using Qiagen RNeasy Lipid Tissue Mini Kit (Germantown, 
MD). After the initial lysis in Qiazol buffer, the aqueous fraction was used for RNA isolation 
according to the supplied protocol, including an on-column DNA digestion (RNase-free 
DNase set, Qiagen). Collection of RNA from cell culture was performed using a Nucleospin 
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RNA mini kit (Takara, Kusatsu, Japan). The RNA concentration was determined with a 
NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and 0.2 µg (cell 
culture) or 0.5 µg (rat tissue) RNA underwent reverse transcription using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Five microliters of 1:20 dilution of 
cDNA was applied in technical duplicates to white PCR plates (Bio-Rad Laboratories) and 
incubated in a mix of appropriate primers and hydrolysis probes (450 nM and 100 nM, 
respectively) and Universal TaqMan Master Mix (Thermo Fisher Scientific) for a final 
volume of 20 µl. Target sequences, which included GLuc, GFP,RNA polymerase II 
(PRNAII), and ubiquitin-conjugating enzyme E2I (Ube2i), were amplified using BioRad 
CFX96 with 50 cycles of 20 s at 94°C and 1 min at 60°C. The transgene cycle threshold (Ct) 
values were estimated with the Bio-Rad CFX Manager software using single threshold mode, 
and normalized to the geometric mean of the Ct values for the reference genes. Fold change in 
gene expression was calculated using 2-∆∆Ct and the results are expressed as fold change with 
upper and lower limits determined using the standard deviation (SD) for ∆Ct. The following 
sequences were used for target amplification and detection: GLuc, cacgcccaagatgaagaagt 
(forward), gaacccaggaatctcaggaatg (reverse), tacgaaggcgacaaagagtccgc (FAM/BHQ-labelled 
probe); eGFP, agcaaagaccccaacgagaa (forward), ggcggcggtcacgaact (reverse), 
cgcgatcacatggtcctgctgg (FAM/BHQ-labelled probe); hM3Dq, tctggcaagtggtcttcatc (forward), 
ttaccaggatgttgccgatg (reverse), ctttcttaacgggcatcctggcc (FAM/BHQ-labelled probe); hM4Di, 
catcccacaatcgctatgag (forward), acagtcaccaggctcagg (reverse), cctgtcactgtggcaatgaagacc 
(FAM/BHQ-labelled probe); PRNAII, tagtcctacctactccccaacttc (forward), 
agtagccaggagaagtgggag (reverse), actcgcccaccagtcccacctact (HEX/BHQ-labelled probe); 
Ube2i, gccaccactgtttcatccaaa (forward), gccgccagtccttgtcttc (reverse), 
cgtgtatccttctggcacagtgtgc (HEX/BHQ-labelled probe). 
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For isolation of DNA, the interphase and organic phase from the initial lysis with Qiazol were 
used. DNA was precipitated with 100% ethanol, and the DNA pellet washed three times in 
0.1 M sodium citrate in 10% ethanol. After a final wash in 75% ethanol, the DNA pellet was 
air-dried and then resuspended in 8 mM NaOH, with subsequent adjustment of pH with 100 
mM HEPES and 100 mM EDTA. After determination of DNA concentration, the samples 
were diluted to 1000 rat genomes / 5 µl (635.7 pg DNA /µl). The DNA was applied as 
technical triplicates to a semi-skirted 96-well PCR plate (Eppendorf AG, Hamburg, Germany) 
along with ddPCR Supermix for Probes (Bio-Rad Laboratories) and GLuc and Ggt1 primers 
(450 nM) and hydrolysis probes (100 nM) in a 25 µl reaction mix. After droplet generation 
(Automated Droplet Generator, Bio-Rad Laboratories), the target genes were amplified using 
40 cycles of 20 s at 94°C and 1 min at 60°C (T100 Thermal Cycler, Bio-Rad Laboratories). 
The number of positive and negative droplets was estimated with the QX200 Droplet Reader 
and QuantaSoft software (Bio-Rad Laboratories) using absolute quantification mode. The 
oligonucleotides used for Ggt1 amplification and quantification were ccaccccttccctactcctac 
(forward), ggccacagagctggttgtc (reverse), ccgagaagcagccacagccatacct (HEX/IBFQ-labelled 
probe). 
 
MethAb expression 
The expression plasmid pAAV-MethAb, encoding both heavy- and light-chains of the Meth-
specific monoclonal antibody (MethAb), was constructed as described in a previous study 
(Figure 5).22 HEK293 cells were seeded (5×104 cells/cm2) in 24-well plates and grown as 
monolayers in the growth medium (DMEM supplemented with 10% heat-inactivated FBS, 
100 U/ml penicillin, and 100 µg/ml streptomycin) overnight at 37°C in a humidified incubator 
with 5% CO2. Cells were then transfected with pAAV-MethAb (0.5 µg/well) using jetPEITM 
transfection reagent (Cat. No. 101-10N, Polyplus-transfection, France) as directed by the 
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manufacturer. Two hours later, cells were incubated with fresh growth medium supplemented 
without or with Meth (100 µM) for 20 hours. After that, the total RNA was purified by Trizol 
reagents (#1559608, Invitrogen) and then subjected to reverse transcription for cDNA 
synthesis using RevertAid First Strand cDNA Synthesis Kit (#K1622, Thermo Fisher 
Scientific). The synthesized cDNA were used as templates in the quantitative polymerase 
chain reaction (qPCR) analysis, performed on the ABI StepOnePlus system. Briefly, 2 µl of 
diluted cDNA, 10 µl of 2× SYBR green PCR master mix (#K0371, Thermo Scientific), and 2 
µl of each primer (5 µM) were mixed in distilled water to a final volume of 20 µl. The PCR 
cycling program was set as follows: 50˚C for 1 minute and 95˚C for 10 minutes, followed by 
40 cycles of denaturation at 95˚C for 15 seconds and annealing/extension at 60˚C for 1 
minute. The primers used for the qPCR were listed as the following: MethAb, 5’-
GCCTCGTGAAACCTTCTCAG-3’ (forward), 5’-CCGAATCCAGCTCCAGTAAC -3’ 
(reverse); beta-actin, 5’-CATTGCTGACAGGATGCAGAAGG-3’ (forward), 5’-
TGCTGGAAGGTGGACAGTGAGG-3’ (reverse); GADPH, 5’-
CATCACTGCCACCCAGAAGACTG-3’ (forward), 5’-
ATGCCAGTGAGCTTCCCGTTCAG-3’ (reverse). The mRNA levels of MethAb were 
normalized to that of beta-actin or GAPDH and presented as fold changes relative to control 
(pAAV-MethAb + 0 µM Meth). 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 7 or IBM SPSS Statistics. Test 
details can be found in the main text or corresponding figure legend. Statistical significance 
was considered when the p-value was < 0.05. 
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Figure legends 
Figure 1. Subcutaneous methamphetamine activates the CMV promoter in rat brain. See also 
Figure S1. (A) Timeline for studying the effect of methamphetamine (Meth) on transgene 
expression and secretion. (B) Fluctuations in CSF GLuc activity following administration of 
Meth (2.5 mg/kg x 4) in rats with striatal overexpression of CMV-GLuc (n = 3-4). 
****p<0.0001 compared to saline (treatment effect F1,6 = 17.23, p = 0.0060 with two-way 
ANOVA, and Sidak’s test), and to all other time points within the group (one-way ANOVA 
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F5,20 = 30.45, p < 0.0001, and Tukey’s test). (C) CMV-GLuc expression levels determined 
with real-time RT-qPCR in the striatum 8 h after the first Meth/saline injection (n = 3-4, p = 
0.0292, t(5) = 3.028 with unpaired t-test of ∆Ct values). (D-G) Measurements of (D, F) CSF 
GLuc activity and (E, G) striatal GLuc mRNA in rats intrastriatally transduced with (D, E) 
AAV1-Syn1-GLuc or (F, G) AAV1-EF1α-GLuc. (D, F) Two-way ANOVA treatment effect, 
(D) n = 4, F1, 6 = 0.0004065, p = 0.9846; (F) n = 3, F1, 4 = 0.02145, p = 0.8906; (E, G) unpaired 
t-test, (E) n = 4, t(6) = 0.8211, p = 0.4430; (G) n = 4, t(6) = 0.9038, p = 0.4009. Results from 
GLuc activity are shown as mean ± SD. Expression results are shown as 2-∆∆Ct ± upper and 
lower limits with individual ∆∆Ct values plotted. 
 
Figure 2. CMV-driven expression of striatal GFP reporter increases following multiple or 
single doses of methamphetamine. (A) Transgene mRNA levels in the striatum of rats 
overexpressing GFP under the CMV’ or CMV promoter following s.c. injections of saline or 
methamphetamine (Meth 2.5 mg/kg x 4) (n = 4, *p<0.05, ***p<0.001, unpaired t-test of ∆Ct 
values; CMV’: t(6) = 8.744, p = 0.0001; CMV: t(6) = 3.538, p = 0.0122). (B) Transgene 
expression levels in the striatum of GFP-transduced, 6-OHDA-lesioned rats 0, 2, 4, and 8 h 
after a single injection of 2.5 mg/kg Meth (n = 4-5, one-way ANOVA, F3, 13 = 2.608, p = 
0.0960; unpaired t-test 0 h vs 4 h, t(7) = 2.357, p = 0.0505). Results are presented as s 2-∆∆Ct ± 
upper and lower limits with individual ∆∆Ct values plotted. 
 
Figure 3. Excitatory amino acids activate the CMV promoter in vitro. (A-G) Primary cortical 
neurons transduced with AAV1 vectors coding for GLuc under the CMV, Syn1, or EF1α 
promoter were treated with 100 µM kainic acid (KA) or glutamate (Glut) for 24 h, with 
subsequent analysis of (A-C) extracellular and (D-F) intracellular GLuc activity, and (G) cell 
viability (MTS assay). n = 5-10, *p<0.05, ****p<0.0001 with one-way ANOVA; (A) F2, 18 = 
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118.5, p < 0.0001; (B) F2, 19 = 56.8, p < 0.0001; (C) F2, 20 = 5.381, p = 0.0135; (D) F2, 18 = 
1083, p < 0.0001; (E) F2,20 = 121.8, p < 0.0001; (F) F2,20 = 50.79, p < 0.0001; (G) F2,21 = 
54.12, p < 0.0001, followed by Dunnett’s multiple comparison test. Results are shown as 
mean ± SD. 
 
Figure 4. Induction of CMV-driven transgene expression following activation of Gq 
signaling. See also Figure S2. (A, B) Primary cortical neurons overexpressing hM3D (Gq) or 
hM4D (Gi) in combination with GLuc under the CMV’ promoter were treated with CNO (0-3 
µM) for 24 h, with subsequent analysis of (A) extracellular GLuc activity or (B) GLuc mRNA 
levels. Results are shown as (A) mean ± SD or (B) 2-∆∆Ct ± upper and lower limits. (A, B) 
***p<0.001 and ****p<0.0001 vs 0 µM CNO, ## p<0.01, ###p<0.001, ####p<0.0001 vs 
0.03 µM CNO, one-way ANOVA [(A) n=3, hM3D: F3,8 = 82.25, p<0.0001; hM4D: F3,8 = 
0.952, p = 0.4604; (B) n = 9, hM3D: F3,32 = 63.95, p<0.0001; hM4D: F3,31 = 3.116, p = 
0.0402] and Dunnett’s test. 
 
Figure 5. Methamphetamine enhances CMV-driven expression of MethAb. (A) Construct for 
methamphetamine (Meth)-specific monoclonal antibody (MethAb) expression. The heavy- 
and light-chain gene sequences of MethAb were cloned in the expression plasmid pAAV-
MethAb, and their expression was driven by the cytomegalovirus promoter (CMV). Linker-
2A = a sequence composed of a furin cleavage site (RKRR), a V5 epitope, a spacer peptide 
(SGSG), and a 2A self-cleavage sequence; SP = secretion signal peptide; WPRE = 
woodchuck hepatitis B virus post-transcriptional regulatory element; 6xHis = 6 x histidine 
tag; red line: the target region of the quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) analysis. (B, C) Gene expression of MethAb. HEK293 cells were 
transfected with or without pAAV-MethAb, and two hours later, cells were treated with or 
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without Meth 100 µM for 20 hours. The mRNA levels of MethAb were determined by qRT-
PCR analysis and normalized to ß-actin (B) or GAPDH (C). The relative mRNA levels of 
MethAb are presented as folds of control (pAAV-MethAb + 0 µM Meth). **** p < 0.0001; 
one-way ANOVA followed by Dunnett’s comparison test, data presented as mean ± standard 
error (SEM). 
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